<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2012110711398N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2013-05-04</date_registration>
      <primary_sponsor>Research Deputy of Medicine Faculty, Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Maintaining of remifentanil infusion until extubation</public_title>
      <acronym></acronym>
      <scientific_title>Study of the effects of maintaining remifentanil infusion until tracheal extubation on the recovery profile and hemodynamic variables in the patients with elective craniotomy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2012-08-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>62</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/11656</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Condition 1: Craniotomy of supratentorial lesion. Condition 2: Craniotomy of supratentorial lesion. Condition 3: Craniotomy of supratentorial lesion.</hc_freetext>
      <i_freetext>Intervention 1: In the case group with last skin suture, infusion of propofol will be ceased but the infusion of remifentanil continued with the half dose of surgery time until response to verbal stimulation by patients. Intervention 2: In the control group, with the conclusion of surgery both drugs (propofol &amp; remifentanil) will be discontinued and for blinding infusion of normal saline as placebo will starts.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Amir Hossein Bagheri Aghdam MD.</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Anesthesiolgy Department, Firouzgar Hospital, Beh-Afarin St. Karim Khan Av.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 8214 1360</telephone>
        <email>homopersicus@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Reza Ghodraty MD.</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Anesthesiology, Firouzgar Hospital, Beh-Afarin St. Karim Khan Av.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 8894 6762</telephone>
        <email>m-ghodrati@tums.ac.ir   mrghodrati@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: patients who candidated to supratentorial craniotomy, Age from 18 to 65 years, ASA physical class I-II, preoperative GCS &gt; 13&#13;
&#13;
 Eexclusion criteria: age&gt; 65 &lt;18 years, physical class ASA &gt; II, GCS&lt; 13, any allergy to the drugs of study, history of smoking, COPD, chronic cough, asthma, HTN, difficult airway and recent upper respiratory tract infections</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>D33</hc_code>
      <hc_code>C71</hc_code>
      <hc_code>D43.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Brain, supratentorial</hc_keyword>
      <hc_keyword>تومور بدخیم مغز</hc_keyword>
      <hc_keyword>Brain, supratentorial</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In the case group with last skin suture, infusion of propofol will be ceased but the infusion of remifentanil continued with the half dose of surgery time until response to verbal stimulation by patients.</i_keyword>
      <i_keyword>In the control group, with the conclusion of surgery both drugs (propofol &amp; remifentanil) will be discontinued and for blinding infusion of normal saline as placebo will starts.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Coughing &amp; bucking intensity. Timepoint: during tracheal extubation. Method of measurement: Minogue Scale.</prim_outcome>
      <prim_outcome>Mean Arterial Pressure. Timepoint: Each 2 minutes from last skin suture or Mayfield opening  until extubation and each 2 minutes after extubation until 10 minute later/each 5 minutes until 15 minute later in recovery room. Method of measurement: Automatic noninvasive sphigmomanumeter.</prim_outcome>
      <prim_outcome>Heart rate. Timepoint: Each 2 minutes from last skin suture or Mayfield opening  until extubation and each 2 minutes after extubation until 10 minute later/each 5 minutes until 15 minute later in recovery room. Method of measurement: Pulse oximeter.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Time interval to awakening after discontinuing of anesthesia drug. Timepoint: Verbal stimulation every min after discontinuing of propofol. Method of measurement: Time to opening of eye with stimulation by cornometer.</sec_outcome>
      <sec_outcome>Nausea &amp; vomiting pervalance and intensity. Timepoint: Each 15 minutes until 1 hour in recovery room. Method of measurement: Four points score: 1 no sign, 2 mild, 3 moderate, 4 severe.</sec_outcome>
      <sec_outcome>Concsiousness level. Timepoint: Each 15 minutes until 1 hour in recovery room. Method of measurement: GCS (Glasco coma scale).</sec_outcome>
      <sec_outcome>Reoperation incidance rate. Timepoint: Till 48 houres after operation. Method of measurement: Sergeon's decision.</sec_outcome>
      <sec_outcome>Arrythemia incidance rate. Timepoint: After the last suture or Mayfield opening till O.R abondonment. Method of measurement: Contineous ECG monitoring.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Research Deputy of Medicine Faculty, Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2013-02-16</approval_date>
        <contact_name>Tehran University Of Medical Sciences Ethics Committee</contact_name>
        <contact_address>Tehran University Of Medical Sciences, Ghods St. Keshavarz Blvd. tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
